Latest Industry Insights

Only 10 years ago, Nobel prize-winning work introduced CRISPR as a new and powerful genome editing tool. Here, three noteworthy applications of the technology are highlighted.

Technology Networks recently had the pleasure of speaking with Mark Fidock, vice president for Diagnostic Development, Precision Medicine at AstraZeneca, to find out how the company is “rising to the challenge” of delivering precision medicines for chronic diseases.

BYOD has become an essential cornerstone of modern clinical trials. This article discusses the adoption of BYOD and the benefits it can bring to patients.

In this article, Technology Networks speaks with Mindset Pharma CEO James Lanthier about how patents work in the fast-changing psychedelics industry, what makes a patent effective and how newer compounds stack up against natural psychedelics.

In this interview, we speak to research scientist Tobias Whelan, who is conducting a first-ever mechanistic study of psilocybin in autistic adults to understand how the serotonin system may differ in autistic and non-autistic individuals.

Chris Sigley highlights some of the main findings from the Ethical Medicines Industry Group and Arkivum’s annual survey tracking the progress of digital transformation and clinical data strategies of 305 global life sciences organizations.

Technology Networks recently had the pleasure of speaking to Dr. Philip Empey, to learn more about the Pharmacogenomics Center for Excellence and how it is working to prove the clinical utility of predictive PGx testing.

In this interview with Bryan Kobel, CEO of TC Biopharm, we find out about gamma-delta T-cell therapy, including how it works, its applications and how TC Biopharm developed its pioneering gamma-delta treatment for acute myeloid leukemia.

To understand how machine learning methods and new software capabilities are helping proteomics researchers gain greater depth in their analyses, Technology Networks recently interviewed Tharan Srikumar, product manager in bioinformatics at Bruker Daltonics.

Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.